#USA #Salt Lake City #Sera Prognostics #PreTRM Test #PRIME Study

Sera Prognostics Financial Update for Q2 2025

Sera Prognostics Inc., also known as The Pregnancy Company®, has made waves in the healthcare sector with its recent quarterly financial report for Q2 2025, published on August 6, 2025. As a company dedicated to enhancing maternal and neonatal health through pioneering pregnancy biomarker information, Sera has showcased not only its dedication to innovation but also its commitment to transparency and stakeholder engagement.

Financial Highlights

In the latest report, Sera Prognostics recorded a revenue of $17,000 for the second quarter, down from $24,000 in Q2 of 2024. This dip in revenue reflects the transition stage of the company as it pivots towards commercialization following the pivotal PRIME study.

Operating expenses stood at $9.3 million, consistent with the previous year. Notably, the company has seen a 24% reduction in research and development costs, dropping to $3.3 million as the pivotal PRIME study has concluded. As the company readies for its market launch, it has increased its selling, general, and administrative expenses to $6.0 million compared to $4.9 million last year, indicative of strategic investments in its growth and outreach programs. Sera's net loss for the quarter was $8.0 million, slightly improved from $8.3 million in the same period of the previous year.

Strategic Developments

The report highlighted significant advancements in Sera’s strategic initiatives, particularly involving engagement with Medicaid plans in various states characterized by higher premature birth rates. This initiative outlines Sera's proactive approach in identifying and capitalizing on commercial opportunities—especially in states where there exists an urgent need for improved maternal health solutions.

Furthermore, Sera is poised to release the comprehensive results of its pioneering Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study by the end of this year. This study is expected to provide in-depth insights into health economic benefits and potential cost savings for Medicaid programs through the implementation of Sera’s PreTRM Test.

Leadership Enhancements

In tandem with its operational advancements, Sera Prognostics has strengthened its leadership. Notably, Lee Anderson has been appointed as Chief Commercial Officer, leveraging 30 years of experience in sales and marketing within the healthcare space. Additionally, Chuck Hyde has joined as Head of Market Access, and Jennifer Zibuda is now leading Investor Relations. These appointments signal Sera's commitment to enhancing its commercial strategy and investor engagement as it prepares for anticipated revenue growth and market presence.

Company Vision and Future Outlook

Zhenya Lindgardt, Sera's President and CEO, expressed optimism regarding the company's trajectory. He stated, "We continue to build the foundation needed for the expected acceleration in commercial momentum now that our full PRIME pivotal study results are in hand." This emphasizes the company’s steadfast belief in the potential of its PreTRM test to significantly mitigate the issues stemming from premature births.

As the company looks forward, it holds approximately $108.5 million in cash and securities, providing ample runway for achieving its objectives through 2028. Sera aims to enhance its outreach and solidify its market position within the prenatal healthcare sector.

About Sera Prognostics

Founded with the goal of advancing women's and children’s health, Sera Prognostics offers cutting-edge diagnostic tests like the PreTRM Test, which helps predict the risk of preterm birth. Given the critical nature of preterm births and the accompanying medical complications, Sera's advancements have the potential to revolutionize how expectant mothers are cared for, ensuring better health outcomes and reduced overall healthcare costs.

Through these combined efforts, Sera Prognostics not only stands at the forefront of maternal health diagnostics but also fosters a brighter future for mothers and their newborns.